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Abstract: Human papillomavirus (HPV) E6 and E7 oncoproteins are critical for development and
maintenance of the malignant phenotype in HPV-induced cancers. These two viral oncoproteins
interfere with a plethora of cellular pathways, including the regulation of cell cycle and the control
of apoptosis, which are critical in maintaining normal cellular functions. E6 and E7 bind directly
with certain components of the Ubiquitin Proteasome System (UPS), enabling them to manipulate a
number of important cellular pathways. These activities are the means by which HPV establishes an
environment supporting the normal viral life cycle, however in some instances they can also lead
to the development of malignancy. In this review, we have discussed how E6 and E7 oncoproteins
from alpha and beta HPV types interact with the components of the UPS, and how this interplay
contributes to the development of cancer.
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1. Introduction
Papillomaviridae is a diverse family of small, non-enveloped DNA viruses, approximately 50–60
nm in diameter that infect all homoeothermic vertebrates including humans [1,2]. Interestingly, recent
studies have also detected members of Papillomaviridae in fish [3]. Currently, there are known to be
approximately 200 different human papillomavirus (HPV) types, which are classified in five genera
(alpha, beta, gamma, mu and nu) [4]. The Alphapapillomavirus species (α-HPVs) preferentially infect
oral or anogenital mucosa in humans and primates [2]. The α-HPVs are further classified as low-risk
(LR) (e.g., HPV-6 and HPV-11) or high-risk (HR) (e.g., HPV-16, HPV-18, and HPV-33), based on their
association with human cancers [1]. HPV infections are usually fairly rapidly cleared by the immune
system–from a few months up to two years from initial viral entry. However, in some instances, the
infections are not neutralized by the immune system and they persist for long periods, which can
result in the development of different types of neoplasia [5]. LR HPV types cause self-limiting benign
anogenital warts and are only rarely found in squamous intraepithelial lesions, possibly as a part of
multiple infections [6,7]. On the other hand, HR HPVs have been recognized as the main causative
agent of cervical cancer, with more than 600,000 new cases annually worldwide [1,2,8,9]. HPV-16
and HPV-18 are associated with approximately 80% of cervical cancer globally, while the remaining
20% are linked to infection by other HR HPVs (e.g., HPV-31, HPV-33, HPV-45, and HPV-58) [1,8,10].
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HPVs also cause different types of anogenital cancers and were shown to be associated with 30–50% of
head-and-neck cancers (HNC), particularly affecting the oropharynx, the base of the tongue, and the
tonsils [1,11–15]. Intriguingly, HPV-16 is the predominant cancer-causing type associated with the vast
majority of HPV-positive HNCs, with other HR types being detected only sporadically [13,14].
The Betapapillomavirus genus comprises approximately 50 HPV types and can be detected in
normal and precancerous tissue, as well as in cancerous cutaneous epithelial tissue [2,16]. Although
β-HPVs are primarily considered to be non-carcinogenic in the general population, some β-HPV types,
such as HPV-5 and HPV-8, can represent a potential cancer risk in particular hypersensitive groups
(e.g., in cases of severe immunodeficiency and in epidermodysplasia verruciformis patients), where
β-HPVs have been found in skin warts and in cutaneous squamous cell carcinomas (CSCC) [17,18]. In
addition, these β-HPVs are also characterized as co-factors, which, in combination with ultraviolet
(UV) irradiation, have been thought to contribute to the development of non-melanoma skin cancers
(NMSC) [16]. This was later questioned and it was proposed that loss of T-cell immunity, rather than
HPV activity, increased the risk of CSCC in immunosuppressed patients [19].
It is believed that HPVs infect cells in the basal layer of stratified squamous epithelia, exposed as a
result of small abrasions and micro-wounds [20,21]. In normal epithelium, epithelial cells in the basal
layer are proliferative, while the differentiating cells in the suprabasal layers have exited the cell cycle.
The HPV life cycle is dependent upon the replicative machinery of basal cells, which have the potential
to proliferate. Following infection, HPV genomes are established as extrachromosomal elements or
episomes. Transition to the late stage of HPV infection is followed by the expression of late genes
and virion production [20,22]. Although, in the majority of cases, HPV infection is asymptomatic or
transient, in some individuals the viral genomes become integrated into the host DNA, with much of
the viral genome being lost, which results in a breakdown of the productive life-cycle of the virus. In
addition, integration of viral DNA usually leads to the upregulated expression of the early viral genes
E6 and E7, resulting in increased proliferation of the infected cell, which is a crucial step in further
malignant development [15,23,24]. However, there may potentially be integration that does not lead to
increased E6/E7 expression, therefore not inducing a carcinogenic effect.
The β-HPV types infect the basal layer of the squamous epithelium and hair follicle region, but
the mechanism remains unknown [25,26] although some β-HPVs, like HPV38, show similarities
with mucosal HR types and were associated with cancer development through E7/Rb protein
interactions [27,28]. Interestingly, while the viral integration of HR HPV types is considered to
be one of the key events in the process of tumor formation and in maintenance of the transformed
phenotype, this appears not to be the case with β-HPVs [29]. Studies have demonstrated that the
process of viral integration is absent during β-HPV infections and there is no requirement for continual
oncoprotein expression to allow the persistence of the transformed phenotype during CSCC, indicating
that β-HPVs contribute to the initial steps of tumor formation, but are not necessary for its continued
maintenance [16,17,28,30,31].
2. The Ubiquitin Proteasome System
The Ubiquitin Proteasome System (UPS) is the pathway responsible for the majority of intracellular
protein degradation in eukaryotic cells. It controls the turnover of thousands of short-lived, regulatory,
damaged and misfolded proteins, in order to regulate and maintain various cellular functions and
cellular homeostasis [32]. It is a highly specific process and involves the addition of ubiquitin molecules
to cellular substrates, which consequently leads to their modification via various cellular pathways.
Fundamental cellular signaling pathways that are regulated by ubiquitination include cell cycle control,
cell survival, cell proliferation, transcription, DNA repair, apoptosis, cellular metabolism, protein
quality control, and membrane trafficking, as well as ubiquitination being very important in the
immune response [33–35]. Ubiquitination, which involves a complex interplay of ubiquitinating and
deubiquitinating enzymes (DUBs), is an essential element of control by the UPS [36,37]. Ubiquitin is
transferred to target proteins by the ubiquitination cascade: first, ubiquitin is activated and bound
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by an E1 ubiquitin-activating enzyme, then transferred to an E2 ubiquitin-conjugating enzyme and,
finally, transferred to lysine residues on the target protein by E3 ubiquitin-protein ligase [36,37]. So
far, studies have identified two E1 activating enzymes, 40 E2 conjugating enzymes, around 800 E3
ubiquitin-protein ligases and about 100 DUBs [38]. While all components of the UPS are of great
importance for ubiquitination, individual ubiquitin-protein ligases may be valuable viral targets as
they are involved in substrate recognition, and hence define the specificity of the system. They are
categorized into two main families: the numerous Really Interesting New Gene (RING) finger E3
ubiquitin ligases; and the less common Homologous to E6-associated protein C-Terminus (HECT)
domain E3 ligases [39,40]. Polyubiquitin chains attached to substrates via lysine 48 will result in target
protein degradation at the proteasome, while polyubiquitin chain attachment to other lysines will
modulate proteasome-independent activities [41]. Proteins can also be mono-ubiquitinated, and this
influences processes such as endocytosis and vesicular sorting [42]. On the other hand, ubiquitin
molecules are cleaved from substrates by DUBs [43], which play essential roles in cellular processes
as diverse as DNA replication, gene silencing, and endocytosis, ultimately affecting cell growth
and oncogenesis.
3. HPV and the UPS
Many human pathologies, such as inflammatory and neurodegenerative diseases and certain
cancers are, directly or indirectly, promoted by the deregulation of the UPS [32,44]. An intriguing
feature of both HPV oncoproteins, E6 and E7, is their ability to direct many of their cellular substrates
for proteasome-mediated degradation [21,45]. Those interactions were either shown or confirmed using
methods like co-immunoprecipitation, Glutathione-S-transferase (GST)-fusion protein pull-down,
affinity chromatography, Yeast Two Hybrid Assay and/or Tandem Affinity Purification and Gaussia
princeps luciferase protein complementation assay. HPV E6 and E7 proteins appear to have evolved
various strategies to make use of the ubiquitin system to support the viral lifecycle [45–47]. In particular,
to avoid apoptosis, E6 mainly targets p53 while, by targeting the pRb, p107 and p130 pocket proteins,
E7 induces cell cycle progression [48–50]. E6 proteins from high-risk [51] and low-risk [52,53] HPVs
are able to bind p53, and it was further shown that this binding promotes the degradation of p53 via
the ubiquitin pathway [48]. Interestingly, E6 proteins from both high- and low-risk HPVs were also
shown to have the capacity to bind p53 but without inducing its degradation [54,55]. Furthermore,
a recent study showed that in the case of beta HPVs, HPV17a, HPV-38, and HPV-92 E6s could bind
and/or stabilize p53 [56].
E6 and E7 oncoproteins inactivate the majority of these cellular substrates by interacting with
components of the UPS, ultimately inducing their degradation at the proteasome. Among the diverse
components of the UPS, the interplay between E6/E7 and ubiquitin ligases is one of the crucial
aspects in this process. The best characterized ubiquitin ligases used by the two oncoproteins are
E6-associated protein (E6AP) and the cullin-2 ubiquitin ligase complex [57]. E6AP complexes with E6
and is involved in targeting p53 and some other targets, while E7 uses the cullin-2 ubiquitin ligase
complex to target pRb [48,58]. To date, this interaction has only been shown for HPV16 E7 [57]. There
are also additional ubiquitin ligases and other components of the UPS, which are directed for similar
activities by the viral oncoproteins [46,59–63]. Furthermore, HPV oncoprotein interactions with the
UPS are not only critical for successful viral replication, but are also necessary for maintenance of the
transformed phenotype [15,45]. Studies have shown that interference with components of the UPS
has a down-regulatory effect on the ability of HPV-transformed cells to proliferate indefinitely and to
avoid apoptosis [46,47,62–64]. Therefore, a better understanding of the interplay between HPVs and
the UPS would provide important novel information and greatly improve our understanding of the
viral life cycle and the process of HPV-induced tumorigenesis.
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4. HPV E6 Oncoprotein and the UPS
The HPV E6 oncoprotein contains around 150 amino acids and has two zinc fingers created by
four CXXC motifs [65–67]. The integrity of these motifs is crucial for optimal oncoprotein function
and they are highly conserved between all HPV E6 oncoproteins identified so far [68,69]. Recent
studies have characterized the crystal structure of the intact E6 oncoprotein and also support the
fact that E6 forms interactions with a large number of cellular substrates [67,70–73]. Recent studies
have characterized the crystal structure of the intact HPV-16 E6 oncoprotein and specific domains
of HPV-18 E6, HPV-51 E6 and Bovine Papillomavirus 1 (BPV-1) E6, and these data all show that E6
forms interactions with a large number of cellular substrates [70,72,74]. HPV E6 complexes with these
substrates through a number of conserved binding motifs. One of these is the so-called PDZ-binding
motif (PBM), exclusively present on the C-terminus of HR HPV E6 oncoproteins, through which they
bind to numerous PDZ-domain containing proteins [10,61]. Another conserved binding motif on E6
is the LXXLL binding motif. The most notable E6 targets with an LXXLL motif include E6AP, the
preferred interacting partner of α-HPV E6 oncoproteins, and MAML-1, interacting with β-HPV E6
oncoproteins [75–80]. As mentioned above, E6 oncoproteins from both α- and β-HPV types interact
with multiple components of the UPS; these interacting partners and their corresponding cellular
functions are summarized in Table 1. By interacting with UPS components, HPV E6 oncoproteins
can modulate various cellular functions, which are shown in Figure 1 and will be discussed in more
detail below.
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Figure 1. The Ubiquitin Proteasome System (UPS) dependent activities of α- and β-HPV E6
oncoproteins. E6 oncoproteins from α and β types interact with various components of the UPS and
as speculated use them to modulate a number of cellular processes. By interacting with the UPS
components high-risk (HR) α-type HPV E6s are involved in the egulation of all the processes sho n
above; low-risk (LR) α-type E6s are involved in regulation of viral life cycle, modulation of E6AP
activity, and regulation of the immune response; β-type HPV E6s are involved in regulation of the viral
life cycle, modulation of E6AP activity, regulation of the immune response, and E6 oncoprotein stability.
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Table 1. HPV E6 interactions with ubiquitin-proteasome system components.
Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
LR HR
580 BARD1
Breast Cancer 1 Gene
(BRCA1)- associated
RING domain protein 1
Putative tumor suppressor gene mutated cancers. Homologous to
BRCA1 RING motif and BRCT domain. BARD1/BRCA1 heterodimer is
disrupted by tumorigenic amino acid substitutions in BRCA1.
Heterodimer is required for BRCA1 tumor suppression and increases
stability of both proteins.
− + ? Yeast-twohybrid, co-IP Yim et al. (2007)
672 BRCA1 Breast Cancer type 1susceptibility protein
Tumor suppressor. The E3 ubiquitin-protein ligase component of
BARD1/BRCA1 heterodimer. BRCA1/BARD1 heterodimer coordinates
DNA damage repair, ubiquitination and transcriptional regulation to
maintain genomic stability.
? + ? IP, GST-pulldown
Zhang et al.
(2005)
4850 CNOT4 CCR4-NOT transcriptioncomplex subunit 4
E3 ubiquitin-protein ligase, promoting degradation of target proteins.
Involved in JAK/STAT activation − − + IP, MS
White et al.
(2012)
1540 CYLD CYLD lysine 63 (K63)DUB
A lysine 63 (K63) deubiquitinase. Tumor suppressor negatively
regulating NF-κB pathway. Ubiquitinated and degraded during
Hypoxia-induced NF-κB activation to relieve its inhibition of NF-κB
signaling cascade
? + ? An et al. (2008)
8925 HERC1
HECT and RLD domain
containing E3 ubiquitin
protein ligase family
member 1
An E3 ubiquitin-protein ligase accepts ubiquitin from an E2
ubiquitin-conjugating enzyme and then transfers the ubiquitin to
targeted substrates. Involved in membrane trafficking.
− − +
IP, proximity
ligation in situ
assay
Holloway et al.
(2015)
8924 HERC2
HECT and RLD domain
containing E3 ubiquitin-
protein ligase 2
A putative HECT domain E3 ligase. Involved in protein trafficking and
degradation pathways regulating ubiquitin-dependent retention of
repair proteins on damaged chromosomes. Recruited to sites of DNA
damage in response to ionizing radiation. Promotes DNA
damage-induced formation of ‘Lys-63’-linked ubiquitin chains.
<+ + <+ IP, MS
Vos et al. (2009);
White et al.
(2012)
83737 ITCH E3 ubiquitin- proteinligase Itchy
An E3 ubiquitin-protein ligase which is involved in the control of
inflammatory signaling pathways. An essential component of an
ubiquitin-editing protein complex ensuring the transience of
inflammatory signaling pathways by regulating ubiquitin-dependent
signaling events. Involved in the cellular antiviral response.
? + ? GPCA Poirson et al.(2017)
23295 MGRN1 Mahogunin ring finger 1
Has RING- E3 ubiquitin-protein ligase activity in vitro. Involved in
regulation of endosome-to-lysosome trafficking. A negative regulator of
hedgehog signaling.
+ + + GPCA, co-IP Poirson et al.(2017)
23024 PDZRN3 PDZ domain containingring finger 3
A member of the LNX (Ligand of Numb Protein-X) family of RING E3
ubiquitin- protein ligases. Required for vascular morphogenesis and
differentiation of adipocytes, osteoblasts and myoblasts.
− + + GST-pull down
Poirson et al.
(2017); Thomas
and Banks
(2015)
29951 PDZRN4 PDZ domain containingring finger 4
A member of the LNX family of RING E3 ubiquitin-protein ligases. A
suppressor of cell proliferation in human liver cancer cell lines. − + − GPCA, co-IP
Poirson et al.
(2017)
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Table 1. Cont.
Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
LR HR
5684 PSMA3 Proteasome subunitalpha 3
Components of the 20S core proteasome complex involved in
proteolysis of most cellular proteins. Associated with two 19S
regulatory particles, form the 26S proteasome. Involved in ATP-
dependent degradation of ubiquitinated proteins.
+ + + IP-MS/MS White et al.(2012)
5695 PSMB7 Proteasome subunit beta7 + + − IP-MS/MS
White et al.
(2012)
5698 PSMB9 Proteasome subunit beta9 − + − IP-MS/MS
White et al.
(2012)
5700 PSMC1 Proteasome 26S subunit 4,ATPase 1
A component of the 26S proteasome belonging to the heterohexameric
ring of AAA proteins (ATPases associated with diverse cellular
activities). Unfolds ubiquitinated target proteins.
? + ? GST-pull down Tomaic´ et al.(2013)
5701 PSMC2 Proteasome 26S subunit 7,ATPase 2
Components of the 26S proteasome.
+ + + IP-MS/MS
White et al.
(2012);
Tomaic´ et al.
(2013)
5702 PSMC3
Proteasome 26S
regulatory subunit 6A,
ATPase 3
+ + − IP-MS/MS,GST-pull donw
White et al.
(2012);
Tomaic´ et al.
(2013)
5704 PSMC4 Proteasome 26S subunit6B, ATPase 4 + + − IP-MS/MS
White et al.
(2012)
5705 PSMC5 26S proteasomeregulatory subunit 8 ? + ? GST-pull down
Tomaic´ et al.
(2013)
5707 PSMD1
26S proteasome
non-ATPase regulatory
subunit 1
+ + + IP-MS/MS White et al.(2012)
5708 PSMD2 Proteasome 26S subunit 2,non-ATPase 2
Component of the 26S proteasome, binds to the intracellular domain of
tumor necrosis factor type 1 receptor (TNFR1); the binding domain of
TRAP1 and TRAP2 resides outside the death domain of TNFR1.
+ + +
IP-MS/MS,
GST-pull down
White et al.
(2012);
Tomaic´ et al.
(2013)
5710 PSMD4
26S proteasome
non-ATPase regulatory
subunit 4
A major ubiquitin- accepting proteasome subunit. Involved in
maintaining structural integrity of the 19S regulatory particle.
Important in direct and indirect recognition of ubiquitinated substrates
of 26S proteasome by interacting with polyubiquitinated proteins and
directing them to the proteasome for degradation. A critical controlling
factor in regulation of protein degradation at the proteasome.
? + ? IP-MS/MS Tomaic´ et al.(2013)
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Table 1. Cont.
Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
LR HR
5709 PSMD3 Proteasome 26S subunit 3,non-ATPase 3 + + + IP-MS/MS
White et al.
(2012)
9861 PSMD6 Proteasome 26S subunit,non-ATPase 6 + + − IP-MS/MS
White et al.
(2012)
5713 PSMD7 Proteasome 26S subunit,non-ATPase 7 + + − IP-MS/MS
White et al.
(2012)
5714 PSMD8 Proteasome 26S subunit,non-ATPase 8 + + − IP-MS/MS
White et al.
(2012)
5719 PSMD13
26S proteasome
non-ATPase regulatory
subunit 13
+ + + IP-MS/MS White et al.(2012)
10213 PSMD14
26S proteasome
non-ATPase regulatory
subunit 14
Components of the 26S proteasome.
+ + − IP-MS/MS White et al.(2012)
23198 PSME4 Proteasome activatorsubunit 4
A proteasome component that specifically recognizes and promotes
ATP- and ubiquitin-independent degradation of acetylated core histones
during DNA damage response to double-strand breaks.
− + − IP-MS/MS White et al.(2012)
64320 RNF25 Ring finger protein 25 A RING finger- dependent E3 ubiquitin- protein ligase that mediatesubiquitination and stimulates transcription mediated by NF-κB. ? + ? GPCA
Poirson et al.
(2017)
9810 RNF40 Ring finger protein 40
A component of the RNF20/40 E3 ubiquitin- protein ligase complex;
forms a H2B ubiquitin ligase complex in cooperation with the UBE2A or
UBE2B. Supports maintenance of tumorigenic features and
inflammatory signaling by promoting nuclear NF-κB activity.
? + ? GPCA Poirson et al.(2017)
85456 TNKS1BP1 Tankyrase-1-bindingprotein
A subunit of the smaller 1-MDa core of Ccr4-Not complex. Ccr4-Not is
an mRNA deadenylase and has a ubiquitin-protein ligase function. <+ <+ + IP-MS/MS
White et al.
(2012)
7188 TRAF5 TNF receptor associatedfactor 5
Tumor necrosis factor receptor-associated factor (TRAF) protein family.
An adapter protein and signal transducer linked to various signaling
pathways by association with the receptor cytoplasmic domain and
kinases. Involved in cytokine signaling and mediates activation of
NF-κB and JNK. It is also involved in apoptosis.
? + ? GPCA Poirson et al.(2017)
7189 TRAF6 TNF receptor- associatedfactor 6
An E3 ubiquitin-protein ligase that mediates the synthesis of ‘Lys-63’-
linked-polyubiquitin chains conjugated to target proteins and
ubiquitination of unanchored poly- ubiquitin chains. Induces activation
of NF-κB and JUN. An adaptor protein and signal transducer linking
TNFR proteins to different signaling pathways. Plays a role in signal
transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor.
? + ? GPCA Poirson et al.(2017)
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Table 1. Cont.
Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
LR HR
7706 TRIM25 Tripartite motifcontaining 25
An E3 ubiquitin-protein ligase involved in innate immune defense
against viruses. Crucially involved in the interferon response to viral
infection.
+ + + co-IP Chiang et al.(2018)
10422 UBAC1 UBA domain containing 1
A ubiquitin-protein ligase required for poly-ubiquitination and
proteasome-mediated degradation of CDKN1B during G1 phase of the
cell cycle.
A non-catalytic subunit of the KPC Kip1 ubiquitination- promoting
complex.
? + ? GPCA Poirson et al.(2017)
7337 UBE3A Ubiquitin- protein ligaseE3A
An E3-HECT domain- containing ubiquitin- protein ligase. It promotes
its own degradation in vivo. This imprinted gene is maternally
expressed in the brain and biallelically expressed in other tissues. It
plays an important role in regulation of the circadian clock and acts as a
regulator of synaptic development.
<+ + +
Yeast-two
hybrid,
co-crystal x-ray
crystalography,
co-IP
Poirson et al.
(2017);
Storey et al.
(1998); Kao et al.
(2000);
Brimer et al.,
2007;
Thomas et al.
(2013)
23352 UBR4
Ubiquitin- protein ligase
E3 component n-recognin
4
An E3 ubiquitin-protein ligase, a component of the N-end rule pathway.
Recognizes and binds to proteins bearing a specific N-terminal leading
to ubiquitination and subsequent degradation. Forms meshwork
structures involved in membrane morphogenesis and cytoskeletal
organization and regulates integrin-mediated signaling.
− − + IP
White et al.
(2012);
Thomas et al.
(2013)
51366 UBR5
Ubiquitin- protein ligase
E3 component n-recognin
5
Also known as EDD (E3 identified by Differential Display). A HECT
domain-containing E3 ubiquitin-protein ligase component of the N-end
rule pathway. Involved in coordinating the balance between cell cycle
progression and differentiation. A regulator of DNA damage response,
acts as a guard against excessive spreading of ubiquitinated chromatin
at damaged chromosomes, as well as tumor suppressor. Frequently
overexpressed in breast and ovarian cancer.
− + + co-IP, MS
Tomaic´ et al.
(2011);
White et al.
(2012)
9958 USP15 Ubiquitin specificpeptidase 15
A deubiquitinating enzyme of the ubiquitin specific protease (USP)
family. Plays a critical role in ubiquitin- dependent processes through
polyubiquitin chain disassembly and hydrolysis of ubiquitin- substrate
bonds.
− + +
Yeast-two
hybrid, GPCA,
IP
Vos et al. (2009);
Poirson et al.
(2017);
Yaginuma et al.
(2018);
Chiang et al.
(2018)
64854 USP46 Ubiquitin carboxyl-terminal hydrolase 46
A deubiquitinating enzyme that plays a role in behavior by regulating
GABA action. Has little intrinsic deubiquitinating activity and requires
interaction with regulator of deubiquitinating complexes WDR48 (WD
repeat-containing protein 48) for high activity.
− + ? co-IP Kiran et al.(2018)
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Table 1. Cont.
Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
LR HR
7428 VHL Von Hippel-Lindautumor suppressor
VHL is a component of the protein complex that includes elongin C,
elongin B, and cullin-2. An E3 ubiquitin-protein ligase involved in the
ubiquitination and degradation of hypoxia- inducible factor (HIF), a
transcription factor crucial to oxygen-related gene expression.. HPV16
E6 promotes hypoxia- induced Warburg effect through blocking the
association of HIF-1α and VHL
? + ? GPCA
Poirson et al.
(2017); Guo et al.
(2014)
331 XIAP X-linked inhibitor ofapoptosis
A multi-functional protein that regulates apoptosis, modulates
inflammatory signaling and immunity, cell proliferation, cell invasion
and metastasis. An E3 ubiquitin-protein ligase regulating NF-κB
signaling and other target. An important regulator of innate immune
signaling via regulation of Nod-like receptors (NLRs).
? + ? GPCA Poirson et al.(2017)
+ confirmed to interact; +, < confirmed interactions with lower affinity compared to hR-HPV E6; - interactions not detected; ? interactions not tested. Co-IP: co-immunoprecipitation;
GPCA: Gaussia princeps luciferase protein complementation assay, IP-MS/MS: immunoprecipitation-mass spectrometry, IP: immunoprecipitation.
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4.1. E6 Oncoprotein and Ubiquitin Ligases
HPV E6s interact with a number of cellular ubiquitin ligases. E6AP or UBE3A E3 ubiquitin-protein
ligase is the principal ubiquitin ligase that associates with α-HPV E6 proteins. The interaction occurs
via an LXXLL binding motif on E6 and leads to stimulation of E6AP ubiquitin ligase activity [81–83].
This association forms a stable complex between the viral oncoprotein and the ubiquitin ligase, which
then targets a number of cellular substrates for proteasome-mediated degradation, with the p53 tumor
suppressor being the most important cellular target [84]. This activity results in modulations of
various cellular pathways to optimize the cellular environment for a productive viral life cycle, and
in rare cases can initiate the process of carcinogenesis (Figure 1) [75,84–86]. Furthermore, a series
of studies have also indicated that the general transcriptional effects of E6 are mostly dependent on
the presence of E6AP [87]. This observation was further analyzed and supported by more recent
studies, which demonstrated that the stability of α-HPV E6 oncoproteins was strictly dependent
on the presence of E6AP [47]. Since E6AP was initially identified through its interaction with HR
HPV E6-16 and HPV-18 proteins, it was originally thought that this association was exclusive to
HR HPV mucosotropic types [84,85], but further studies showed that a LR HPV type 11 E6 could
also complex with E6AP [83,88]. In addition, in vitro proteomic analysis and mass spectroscopy of
cutaneous HPV cellular binding partners has shown that E6AP is a pulldown partner of E6 proteins
from cutaneous-specific HPV-10 (an α-HPV) and HPV-24 (a β-HPV), indicating that β-HPV types can
also interact with E6AP [82]. Furthermore, β-HPV types 24 and 38 E6 were also shown to form a
complex with E6AP [77,81,82,88]. Interestingly, the interaction of E6AP with HPV-10 and HPV-24 E6
oncoproteins also increases their cellular protein levels indicating a more general dependence of all
HPV types on E6AP for the maintenance of appropriate levels of E6 within the cell [82].
HPV-16 E6 oncoprotein was also shown to interact with HERC2, another putative HECT
domain-containing E3 ubiquitin ligase [46,89]. Interestingly, it was found that E6AP physically
mediates HPV-16 E6 and HERC2 interaction, which, in turn, can modulate the ubiquitin ligase activity
of E6AP [90]. Subsequently, it was also shown that HERC2 can bind to E6AP in the absence of E6 [91].
Follow-up studies have demonstrated that, besides HPV-16 E6, several other HPV E6 oncoproteins
(from HPV types 33, 52, 18, 45, 6b and 17a), including HR and LR HPV types, as well E6 oncoproteins
from certain cutaneous β-HPV types, also interact with HERC2 [77]. However, the role of HERC2
in the HPV life cycle, and its contribution to the process of HPV-induced malignancy have yet to be
elucidated [90].
UBR5/EDD is another HECT domain-containing E3 ubiquitin ligase, alterations in which have
been linked to carcinogenesis [92,93]. Studies have shown EDD to be bound strongly by HPV-18 E6,
but only weakly by HPV-16 and HPV-11 E6, suggesting that the interaction between E6 and EDD may
be restricted to HPV-18 E6. EDD protein alone can bind independently to both E6 and E6AP, and
it is also involved in regulating the E6/E6AP complex [94]. It appears that EDD regulation of E6AP
expression is independent of E6, but that loss of EDD stimulates the proteolytic activity of the E6/E6AP
complex, significantly increasing the ability of the E6/E6-AP complex to direct the degradation of its
cellular substrates, particularly p53. Thus fluctuations of EDD protein levels might directly affect
the viral life cycle, and influence the development of HPV-induced malignancies [94]. In addition,
it has also been shown that the association of EDD with HR HPV E6 is important in destabilizing
TIP60; a histone acetyltransferase tumor suppressor, thus ultimately contributing to the development
of HPV-induced malignancies [95].
Another E3 ubiquitin ligase that has been shown to interact with HPV E6 oncoproteins is TRIM25,
which is involved in immune system regulation [96,97]. Different HPVs E6 were shown to interact
with TRIM25, including HR HPVs (HPV-16, -18, -33, and -52 E6), LR HPVs (HPV-6 and -11 E6) and
cutaneous β-HPVs (HPV-5 and -8 E6), suggesting that HPV involvement in modulation of immune
surveillance is conserved between different HPV types [98].
The BARD1 protein is a RING heterodimer that interacts with BRCA1, providing the E3 ubiquitin
ligase activity that is required for BRCA1’s tumor suppressor function, as well as coordination of
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ubiquitination to maintain genomic stability [99,100]. BARD1 is a binding partner of HR HPV-16
and -18 E6, and it only interacts with these two HR HPV types, while no association was observed
with LR HPV-11 E6 [101]. Furthermore, HR E6 oncoproteins were shown to interact directly with
BRCA1 in both in vitro and in vivo conditions [102]. Interestingly, these interactions do not stimulate
any degradation of either BRCA1 or BARD1, but the E6-induced increase in hTERT activity was
considerably greater in the presence of BRCA1 than in its absence, suggesting that E6 possibly functions
in part to antagonize the activity of BRCA1 [102]. However, it still remains to be clarified whether
BRCA1 plays a role in the initiation of cervical cancer. In a recent study, Poirson et al. [38] using the
Gaussia princeps luciferase protein complementation assay (GPCA), identified a number of cellular
ubiquitin ligases or substrates with ubiquitin ligase activity as interacting partners of HPV E6 [38].
These studies assembled and screened a library of 590 cDNAs related to the UPS that covered about
50% of the human ubiquitination system, together with co-immunoprecipitation to confirm novel cell
target protein-E6 interaction. Results indicated various new target proteins, including three RING-type
Ub ligases MGRN1, LNX3 and LNX4 [38,103]. MGRN1 was shown to interact with E6 proteins from
LR HPV-6 and HR HPV types 16, 18 and 33, as well as β-types HPV types 8 and 38. Interaction with
LNX4 was restricted to HPV-16 E6, while LNX3 interacted with E6 oncoproteins from HR HPV types
16, 18 and 33 and β-HPV type 8 E6. The other ubiquitin ligases examined in this study were shown
to exclusively bind HPV-16 E6, and they include ITCH, TRAF6, TRAF5, UBAC1, VHL, XIAP, RNF25
and RNF40 [38]. These ubiquitin ligases are associated with the regulation of several different cellular
pathways, however, biochemical and mechanistic analyses to elucidate their roles in the viral life cycle
and in HPV-mediated malignancies are still lacking [38,104].
Interestingly, there are also ubiquitin ligases that interact exclusively with β-cutaneous E6
oncoproteins, for example, HPV-17a and HPV-3 E6 which were reported to interact with 10 subunits
(CNOT1, CNOT2, CNOT3, CNOT4, CNOT6L, CNOT7, CNOT9/RQCD1, CNOT10, C2orf29, and
TNKS1BP1) of the Ccr4-Not multiprotein complex, which has been shown to be associated with
various enzymatic activities including a ubiquitin ligase function [77,105]. White et al. detected
those interactions by using an unbiased proteomic study including immunoprecipitation and mass
spectrometry [77]. In addition, an E3 ubiquitin-protein ligase, UBR4/p600 was characterized as an
interacting partner of cutaneous β-HPV-38 E6 [82], which has been shown to promote tumorigenesis
in transgenic mouse models [28,106]. Moreover, this association was also observed but not validated
in the proteomic analysis of another study [77]. Interaction between E6 and p600 was quite surprising,
since p600 had been previously reported only as interacting partner of E7 [62,63], and more recent
studies have shown that high risk E7 oncoproteins use p600 to target the PTPN14 tumor suppressor for
proteasome-mediated degradation [59,107,108]. Therefore, it would be of a great interest to investigate
the possible role of p600 in HPV-38-induced malignancy. Finally, a study by Holloway et al. [60]
showed that β-HPV-5 E6 uses a specific and unique mechanism to target the proapoptotic factor
BAK by recruiting the HECT domain-containing E3 ubiquitin ligase HERC1, which binds the
apoptosis-promoting BAK protein in UV-damaged, E6-expressing cells. HERC1 specifically targets
BAK in its active conformation, and only in the presence of E6, suggesting that HPV-5 E6 interacts
with HERC1 to redirect its activity towards activated BAK, specifically to abrogate apoptosis of the
infected cell and maintain the virus lifecycle [60].
4.2. E6 Oncoprotein and Deubiquitinating Enzymes
Apart from ubiquitin ligases, there are also other elements of the UPS, such as DUBs, that have
been shown to interact with E6 oncoproteins from α- and β-HPV types. One of these is CYLD lysine 63
(K63) deubiquitinase, a negative regulator of the NF-κB pathway, which was shown to form complexes
with HR HPV-16 and -18 E6, although there was no evidence for direct interaction [109]. Nonetheless,
a study demonstrated that CYLD polyubiquitination and degradation under hypoxic conditions was
E6-mediated. This implies that this mechanism, which E6 employs under hypoxic conditions, is likely
to contribute to an aggressive microenvironment in tumors caused by HPVs; it also suggests that
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prolonged hypoxia-induced NF-κB activation may be specific only to HPV-induced cancers, such as
cervical and head-and-neck cancers [109].
HPV E6 oncoproteins were further reported to interact with two other DUBs: ubiquitin-specific
protease (USP) enzymes, USP15 and USP46 [38]. USP15 was shown to be bound by E6 proteins from
α-HPV types 16, 18, 33 and 6, and β-HPV types 8 and 38. Biochemically it was demonstrated that
USP15 was involved in the regulation of HPV-16 E6 protein stability [98]. Furthermore, HPV E6 protein
forms a ternary complex with USP15 and TRIM25, resulting in the inhibition of immune surveillance
and antiviral responses, thereby exhibiting a direct involvement in immune system regulation [98].
Recently, it was demonstrated that HR HPV-16, -18 and -31 E6 bind to USP46, but that no interactions
were seen with the LR HPV types [110]. Another study also showed that USP46 is required for the
proliferation of HPV-transformed cancers and derived cancer cells, indicating that USP46 can be
essential for the survival of HPV-transformed cancers [110].
4.3. E6 Oncoprotein and the Proteasome
HPV E6 oncoproteins from α- and β-types were also shown to bind directly to the proteasome.
In vitro studies using GST-pull down assays have demonstrated that HR HPV-18 E6 interacts with
several proteasomal subunits, including PSMC1, PSMC5, PSMD2, PSMC3, PSMC4, and PSMC2, while
under the same conditions HR HPV-16 and LR HPV-11 E6 interacts with both subunits PSMD2 and
PSMC1 [111]. Intriguingly, these interactions seem to be independent of E6AP, but the presence of
E6AP does appear to be required for E6 to interact with PSMD4. This tripartite complex enhances the
ubiquitination of PSMD4, an essential subunit of the 19S proteosome regulatory complex [111]. The
HPV E6 oncoproteins from many HPV types can interact with diverse proteasome subunits, albeit
they differ in their interaction profiles and their preferences for binding different proteasome subunits.
These observations were supported by a series of analyses that demonstrated interactions between
multiple α-HPV E6 oncoproteins and PSMA3, PSMC2, PSMC3, PSMD1, PSMD2, PSMD3, PSMD14,
PSMD11, PSMD7, PSMC4, PSMD13, PSMD6, PSMD8, PSMB7, PSMB9 and PSME4 proteasomal
subunits, while a panel of β-HPV E6 oncoproteins interacted only with a few proteasomal subunits,
including PSMA3, PSMC2, PSMD1, PSMD2, PSMD3, PSMD11, and PSMD13 [77,112,113]. Those
analyses included different methods, including affinity chromatography [113], immunoprecipitation
and mass spectrometry [77], as well as the yeast two-hybrid (Y2H) system and tandem affinity
purification [112]. Hence, E6 proteins from α- or β-HPVs exhibit different affinities of binding to
various proteasomal subunits [77]. These observations were additionally confirmed by several other
studies [90,113–117], suggesting the importance of the close association of E6 with the proteasome,
probably through E6AP which directly connects E6 to the proteasome [77].
5. HPV E7 Oncoprotein and the UPS
HPV E7 oncoprotein is a small acidic protein of approximately 100 amino acid residues, having
no significant sequence similarities to any cellular protein, except for the LXCXE motif. The amino
terminus contains two regions similar to the E1A adenovirus proteins: the conserved region 2 (CR2)
and part of CR1 [65]. The E7 oncoprotein also contains CR3, a zinc-binding site formed by two CXXC
domains that function as a dimerization domain [118]. The CR3 domains are similar to those of the
HPV E6 protein, suggesting that a genetic duplication may have occurred early in HPV evolution [119].
E7 has, in addition, sequences related to those of simian vacuolating virus 40 large tumor antigen
(SV40 T), all contributing to the transforming activities of HR HPV E7 oncoproteins [120–123].
The main function of the HPV E7 oncoprotein is to maintain the infected differentiating cell
in a DNA replication-competent state, which it does in part, by targeting the retinoblastoma tumor
suppressor (pRb), a critical regulator of cell cycle progression, which controls the G1 to S-phase
transition [124]. E7 also binds to the pRb-related members of the pocket protein family, p107 and
p130, which assists in driving the cell cycle of the differentiating HPV-infected epithelial cell into
an S-phase-like state, an environment suitable for replication of the viral genome [125]. In order to
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complete these activities, E7 forms interactions with ubiquitin ligases, which are essential elements
of the UPS. In addition, E7 was shown to complex with other components of the UPS, and these
interactions appeared to be important either for the stability of the oncoprotein or for its role in
regulation and modulation of many cellular processes, some of which are summarized in Table 2 and
Figure 2.
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Figure 2. The Ubiquitin Proteasome System (UPS) dependent activities of α- and β-HPV E7
oncoproteins. E7 oncoproteins from α and β types interact with various components of the UPS and
are thought to use them to modulate a number of cellular processes. By interacting with the UPS
components, high-risk (HR) α-type E7s are involved in the regulation of all the processes shown above;
low-risk (LR) α-type E7s are involved in cell migration, apoptosis, regulation of the immune response,
viral life cycle modulation and E7 protein turnover; β-type E7s are involved in cell migr tion, apoptosis,
endosomal trafficking and regulation of the immune response.
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Table 2. HPV E7 interactions with ubiquitin-proteasome system components.
Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
LR HR
8454 CUL1 Cullin-1 A core component of cullin-RING-based SCF E3 ubiquitin- proteinligase complex, which mediates ubiquitination and proteolysis of E7. + + ? IP
Münger et al. (1989); Boyer et al.
(1996); Oh et al. (2004)
8453 CUL2 Cullin-2
A core component of cullin-RING-based ECS E3 ubiquitin- protein
ligase complex. Stabilizes APOBEC3A.
Required for E7-induced degradation of pRB contributing to cell
transformation by dysregulating G1/S cell cycle checkpoints
− + - co-IP
Huh et al. (2007); Narisawa-Saito
and Kiyono. (2007); White et al.
(2012); Xu et al. (2016);
Westrich et al. (2018)
8452 CUL3 Cullin-3
A core component of cullin-RING-based BCR E3 ubiquitin- protein
ligase complexes, which mediate the ubiquitination and
proteasomal degradation of target proteins.
+ + ? co-IP White et al. (2012); Poirson et al.(2017)
90379 DCAF15 DDB1 and CUL4 associatedfactor 15
May be involved in ubiquitination and degradation through a
DBB1-CUL4 E3 protein-ubiquitin ligase. − + −
GPCA,
co-IP Poirson et al. (2017)
253980 KCTD13 Potassium channel tetramer-ization domain 13
A substrate-specific adapter of a BCR E3 ubiquitin-protein ligase
complex required for synaptic transmission. + + +
GPCA,
co-IP
Chen et al. (2009); Poirson et al.
(2017)
112939 NACC1 Nucleus accumbens- associatedprotein 1
A transcriptional repressor and transcriptional corepressor in
neuronal cells through recruitment of HDAC3 and HDAC4
Required to recruit the proteasome from the nucleus to the
cytoplasm and dendritic spines.
? + ? GPCA Poirson et al. (2017)
9148 NEURL1 Neuralized E3 ubiquitin- proteinligase 1
An E3 ubiquitin- protein ligase that activates in vitro ubiquitination
of JAG1, inhibiting malignant cell transformation of
medulloblastoma cells through the Notch pathway.
+ + +
GPCA,
co-IP Poirson et al. (2017)
5700 PSMC1 26S proteasome regulatorysubunit 4 A component of the 26S proteasome. − + ? IP
Berezutskaya and Bagchi (1997);
Ben-Saadon et al. (2004)
84282 RNF135 ring finger protein 135 An E2-dependent E3 ubiquitin-protein ligase, involved in innateimmune defense against viruses. +, < + −
GPCA,
co-IP Poirson et al. (2017)
57630 SH3RF1 SH3 domain containing ringfinger 1
Has an E3 ubiquitin-protein ligase activity. In the absence of an
external substrate, it can catalyze self-ubiquitination. +, < + ? GPCA Poirson et al. (2017)
92799 SHKBP1 SH3KBP1- binding protein 1 SHKBP1 inhibits CBL-SH3KBP1 complex mediated downregulationof EGFR signaling by sequestration of SH3KBP1. + + +
GPCA,
co-IP Poirson et al. (2017)
7126 TNFAIP1 TNF alpha induced protein 1
A substrate-specific adapter of a BCR E3 ubiquitin-protein ligase
complex that mediates the ubiquitination and proteasomal
degradation of RhoA, thereby regulating the actin cytoskeleton and
cell migration. HPV-16 E7 can modulate the responses of its natural
host cell to the closely related cytokines TNF-α.
+ + +
GPCA,
co-IP
Basile et al. (2001); Poirson et al.
(2017)
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Table 2. Cont.
Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
LR HR
7186 TRAF2 TNF receptor associated factor 2
Regulates the activation of NF-κB and JNK and plays a central role
in the regulation of cell survival and apoptosis. An essential
constituent of several E3 ubiquitin-protein ligases. HPV16 E6/E7
switch cells from apoptotic to proliferative fates under TWEAK/Fn14
interaction, possibly by favoring Ras and TRAF2 activation and
modulating TNF receptor expression.
− + + GPCA,co-IP
Cheng et al. (2015); Poirson et al.
(2017)
7187 TRAF3 TNF receptor associated factor 3
Regulates pathways leading to activation of NF-κB and MAP
kinases, and plays a central role in the regulation of B-cell survival.
An essential constituent of several E3 ubiquitin-protein ligase
complexes. Overexpression of TRAF3 enhances p53 and pRb
expression
? + ? GPCA Poirson et al. (2017); Zhang et al.(2018)
9618 TRAF4 TNF receptor associated factor 4
An adaptor protein and signal transducer linking members of the
TNFR family to different signaling pathways. Plays a role in the
activation of NF-κB and JNK, and in the regulation of cell survival
and apoptosis. May interact selectively and non-covalently with E3
ubiquitin- protein ligase enzymes.
? + ? GPCA Poirson et al. (2017)
7188 TRAF5 TNF receptor associated factor 5
An adaptor protein and signal transducer linking members of the
TNFR family to different signaling pathways.
May interact selectively and non-covalently with E3
ubiquitin-protein ligase enzymes.
+ + +
GPCA,
co-IP Poirson et al. (2017)
10346 TRIM22 tripartite motif containing 22
An interferon- induced antiviral protein involved in innate
immunity. May have E3 ubiquitin-protein ligase activity. Activated
by integration of E6/E7 genes.
? + ? GPCA Pett et al. (2006); Poirson et al.(2017)
22954 TRIM32 tripartite motif containing 32 An E3 ubiquitin-protein ligase. It ubiquitinates DTNBP1 andpromotes its degradation. + + +
GPCA,
co-IP Poirson et al. (2017)
493829 TRIM72 tripartite motif containing 72
A muscle-specific protein that plays a central role in cell membrane
repair by nucleating the assembly of the repair machinery at injury
sites. May be involved in proteasome- mediated,
ubiquitin-dependent protein catabolic processes.
− + + GPCA,co-IP Poirson et al. (2017)
114088 TRIM9 tripartite motif containing 9
An E3 ubiquitin- protein ligase, which self-ubiquitinates in
cooperation with E2 enzyme UBE2D2/UBC4. Serves as a targeting
signal for proteasomal degradation.
? + ? GPCA Poirson et al. (2017)
7314 UBB ubiquitin B
Targets cellular proteins for degradation by the 26S proteasome.
Involved in the maintenance of chromatin structure, the regulation
of gene expression, and the stress response.
? + ? GPCA Poirson et al. (2017)
7319 UBE2A Ubiquitin- conjugating enzymeE2A
Accepts ubiquitin from the E1 complex. In association with the E3
enzyme, UBE2A plays a role in transcription regulation by
catalyzing the ubiquitination of histone H2B.
+ + ? GPCA Poirson et al. (2017)
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Gene ID Gene Protein Function α-HPV β-HPV Method Ref.
7332 UBE2L3 Ubiquitin- conjugating enzymeE2L3
Specifically acts with HECT-type and RBR family E3 ubiquitin-
protein ligases. Accepts ubiquitin from the E1 complex and
catalyzes its covalent attachment to other proteins including E7.
? + ? IP Reinstein et al. (2000)
23352 UBR4 Ubiquitin- protein ligase E3component n-recognin 4
Also known as p600. An E3 ubiquitin- protein ligase that recognizes
proteins with specific destabilized N-terminal residues, leading to
their ubiquitination and degradation. May mediate some pRB-
independent transforming activities of HPV-16 E7, but is not
sufficient for cellular transformation as interactions were also found
with low-risk HPV E7 oncoproteins. It is speculated that UBR4
could potentially play a role in viral replication.
+ + + IP Huh et al. (2005); De Masi et al.(2005); White et al. (2012)
8237 USP11 Ubiquitin carboxyl- terminalhydrolase 11
Inhibits degradation of target proteins by the proteasome. Plays a
role in the regulation of pathways leading to NF-κ-B activation.
Augments HPV-16E7 activity in modulating downstream target
genes, such as pRb, Bcl-2, and Cdc-2, suggesting that this interaction
may contribute to cell transformation by HPV-16E7.
? + ? IP Lin et al. (2008); Poirson et al.(2017)
83844 USP26 Ubiquitin carboxyl- terminalhydrolase 26
Involved in the ubiquitin-dependent proteolytic pathway in
conjunction with the 26S proteasome. + + +
GPCA,
co-IP Poirson et al. (2017)
57663 USP29 Ubiquitin carboxyl- terminalhydrolase 29
A thiol-dependent hydrolyser of ester, thioester, amide, peptide and
isopeptide bonds formed by the C-terminal Gly of ubiquitin. − + −
GPCA,
co-IP Poirson et al. (2017)
23032 USP33 Ubiquitin carboxyl- terminalhydrolase 33
A deubiquitinating enzyme involved in centrosome duplication, cell
migration and beta-2 adrenergic receptor/ADRB2 recycling. + + +
GPCA,
co-IP Poirson et al. (2017)
90850 ZNF598 Zinc finger protein 598
An E3 ubiquitin- protein ligase required for terminal stalling of
ribosomes during translation of poly(A) sequences by mediating
ubiquitination of 40S ribosomal protein.
? + ? GPCA Poirson et al. (2017)
+ confirmed to interact; +, < confirmed interactions with lower affinity compared to HR-HPV E7; - interactions not detected; ? interactions not tested. Co-IP: co-immunoprecipitation;
GPCA: Gaussia princeps luciferase protein complementation assay, IP-MS/MS: immunoprecipitation-mass spectrometry, IP: immunoprecipitation.
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5.1. E7 Oncoprotein and Ubiquitin Ligases
A large number of ubiquitin ligases have been reported to be HPV E7 interactors, a principal one
being cullin 2 (CUL2), a core component of the cullin-RING-based ESC (ElonginBC–Cullin–SOCS-box)
E3 ubiquitin-protein ligase complex [126,127]. This interaction occurs via the E7 CR1 domain, as well
as through its C-terminal sequences, and drives cell cycle progression by degradation of pRb and
upregulation of CDK2 and cyclins A and E [58,128]. In fact, interactions between E7 and CUL2 complex
were validated for 17 different HPV types from both the α- (HPV-16, -18, -31, -33, -45, -6b, -55, -74, -2a,
and -57) and β-genus (HPV-8, -25, -98, -17a, -38, -76, and -92) HPV types. Furthermore, it has been
shown that HPV-16 E7-expressing cells require ZER1 (or Zyg11BL), a substrate-specificity factor for a
CUL2-RING ubiquitin ligase [57,129]. ZER1 is required for HPV-16 E7 to bind CUL2 and destabilize
pRb, suggesting that HPV-16 E7 exploits the CUL2–ZER1 complex for pRb degradation. Interestingly,
the ZER1 association appears to be specific only to HPV-16 E7. This may be related to the fact that
ZER1 contains BC and a CUL2-binding site and acts in a complex with elongin B, elongin C, and CUL2,
while HPV-16 E7 interacts with CUL2, and elongin C is required specifically for the binding of ZER1 to
CUL2 [58,130]. Thus, all three proteins interconnect through a number of possible protein interactions.
E7 oncoprotein, similarly to E6, generally has a short half-life, approximately one hour [124]. It has
been shown that E7 is ubiquitinated by the UBE2L3/Cullin 1 (CUL1) complex, followed by degradation
at the proteasome and, to date, this has been observed only with HPV-16 E7 (122–124). CUL1 is a
core component of multiple cullin-RING-based SKP1-CUL1-F-box proteins (SCF) E3 ubiquitin-protein
ligase complexes, which were previously described not only to degrade E7 itself, but also to cause
destabilization and degradation of the p130 pocket protein through its interactions with E7 [131–135].
Therefore, E7 interacts with the SCF ubiquitin ligase complex containing CUL1 and Skp2 and can be
ubiquitinated by the CUL1-containing ubiquitin ligase in vitro and in vivo [131]. Finally, the half-life of
E7 was found to be significantly longer in Skp2 (-/-) mouse embryo fibroblasts (MEFs) than in wild-type
MEFs. Interactions were also observed between cullin 3 (CUL3) and E7 from HPV types 16, 18, 6b,
55 and 8, with a suggestion that the E7 and CUL3 may not interact directly, but probably via some
BTB proteins [57]. In addition, E7 protein turnover is shown to be driven by ubiquitin-dependent
proteolysis and the process itself is regulated by the two E2 ubiquitin-conjugating enzymes, UbcH7
and UBE2A [38,131]. While there are no solid reports about UbcH7 functions, it is known that UBE2A
plays roles in a number of different biological processes and its binding partners include KCMF1 and
UBR4/p600 [136]. Their roles in HPV E7 modulations of various cellular functions will be discussed in
more detail further in the review.
The HPV-16 E7 protein binds to eleven POZ/BTB (Pox virus and Zinc finger/Bric-a-brac Tramtrack
Broad complex) domain-containing proteins (BTBD15, KCTD13, NAC-1/NACC-1, TNFAIP1, SHKBP1,
ZBTB9, ZBTB20, ZBTB32, ZBTB42, ZBTB43 and ZBTB48) [38]. The functions of these BTB proteins
are largely unknown, and a number of different functional roles have been reported for the POZ/BTB
domain, including transcriptional repression [137,138], cytoskeleton regulation [139,140], and protein
ubiquitination [141–143]. POZ/BTB proteins interact with the CUL3-SCF-like E3 ubiquitin ligase
complex, allowing the POZ/BTB domain to recruit substrate molecules for ubiquitination by the CUL3
component of the SCF-like complex [126,144,145]. Furthermore, some BTB domain-containing proteins
have been identified as substrate adaptors of certain CUL3-RING Ub ligases, such as tumor necrosis
factor α-induced protein 1 (TNFAIP1) and the homologous KCTD13 [146]. In addition, some BTB
proteins also have a C2H2-type zinc finger (ZBTB9, ZBTB32, BTBD15, ZBTB48), which is frequently
found in transcriptional activators, and this is consistent with E7 being a major transcriptional
regulator [147]. The majority of these UPS proteins have only been characterized as E7 interacting
partners, and importantly, the biological consequences of these interactions have yet to be investigated
(Table 2). For example, NAC-1 is a POZ/BTB domain-containing transcriptional repressor protein
related to tumor recurrence, and is essential for tumor growth and survival. The interaction between
the BTB/POZ domains of NAC-1 is critical for tumor cell proliferation [143,148]. NAC-1 has been
reported to be highly expressed in a number of human carcinomas, and, especially interestingly,
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NAC-1 is overexpressed in oral squamous cell carcinoma cells from different oral lesions [149,150].
Furthermore, HPV infection induces cytokine production, with TNF-α and related cytokines inducing
various signaling pathways leading to growth arrest, proliferation, or cell death, but can also cause the
expression of TNFAIP1, another POZ/BTB domain-containing protein. HPV-16 E7 oncoprotein was
found to bind TNFAIP1, leading to TNF-α-mediated apoptosis [151].
Among the binding partners that interact with the E7 CR1 is p600 (ubiquitin N-recognin
domain-containing E3 ligase 4) [57,62], a unique 600-kDa retinoblastoma-associated factor that regulates
caspase-mediated programmed cell death known as anoikis [63,107]. The ability of E7 to associate with
p600 is independent of its binding to the pocket proteins and occurs via the N-terminal domain of E7,
thus contributing independently to cellular transformation [62]. Reduction of p600 protein levels results
in a marked decrease in anchorage-independent growth both in HPV-positive and HPV-negative cancer
cells, suggesting that p600 is normally involved in regulating anchorage-independent growth and
cellular transformation. Furthermore, p600 is also involved in the HR E7-induced proteasome-mediated
degradation of PTPN14 in cells derived from cervical tumors [57,59], and this process is independent
of cullin-1 or cullin-2 [57,59]. In support of this, later studies have suggested the requirement for p600
in various processes involving viral life cycle modulation and the development of malignancy, through
its interaction with HPV-16 and HPV-18 E7 [57,62]. In addition, p600 has been shown to bind various
α- (HPV-16, -18, -31, -33, -45, -6b, -55, -74, -2a, and -57) and β-genus (HPV-8, -25, -17a, -38, and -92)
HPV E7 oncoproteins [57]. Since it is clear that p600 binds to E7 proteins from numerous HPV E7 types,
including benign HPV types, this interaction may also have major importance for the virus life cycle.
Furthermore, p600 can interact with KCMF1 in the absence of E7, suggesting the possibility that E7,
KCMF1, and p600 form part of a larger complex in cells. KCMF1 is a RING E3 ubiquitin-protein ligase
and promotes ubiquitination [136]. Furthermore, the interaction between E7 and KCMF1 is also highly
conserved across different HPV types, including interactions with various α- (HPV-16, -18, -31, -33, -45,
-6b, -55, -74, -2a, and -57) and β-genus (HPV-8, -25, -17a, -38, and -92) HPV E7 oncoproteins [57].
Moreover, HPV E7 was found to interact with TNF receptor-associated factors (TRAFs), a family of
E3 ubiquitin ligases associating with the TNF receptor superfamily, and contributing to the activation
of NF-κB and MAP kinases [152]. TRAF2, an anti-apoptotic protein and an essential constituent of
several E3 ubiquitin-protein ligases complexes, was shown to interact with HR HPV types 16, 18 and
33 E7 oncoproteins and also with β-HPV types 8 and 38, while no interaction was detected for LR
HPV E7 oncoproteins [38]. A later study determined that HPV-16-infected keratinocytes exhibited
an increase in TRAF2 expression and, more specifically, TNF receptor profile changes from type 1
to type 2, as well as the cells being more resistant to TNF-α induction of apoptosis [153]. This is
probably responsible, at least in part, for the switch from an apoptotic to a proliferative fate, seen
in HPV-16 infected keratinocytes [153]. Conversely, a unique adaptor protein and ubiquitin ligase,
TRAF3, was found to interact only with HR HPV types 16 and 18 E7 oncoproteins [38]. A further study
showed that increased expression of TRAF3 enhances p53 and pRb expression and decreases HPV
E6 expression in HPV-positive cells, thus inhibiting cell growth, colony formation, migration, and
enhances susceptibility to TNF-α and cisplatin-induced cell death [154]. These findings suggest that
TRAF3 might have a tumor suppressor role, modulating established cancer hallmarks in HPV-infected
cells [154]. Although interactions of TRAF4 and TRAF5 with E7 were detected, their biological effects
on the host cell are yet to be studied [38]. TRAF5 is also an interacting partner of HR E6, as well as
interacting with the E7 of all HPV types examined, including HPV-16, -18, -33, -6, -8 and -38.
Some other ubiquitin ligases that are involved in pathogen recognition and which associate with
E7 are members of the TRIM family [38]. This comprises a number of proteins involved in many
biological and antiviral processes, and E7 oncoproteins from many different HPV types interact with
TRIM9, TRIM22, TRIM32 and TRIM72; some of these interactions have been further characterized
and confirmed by co-immunoprecipitation, including that between E7 and TRIM32 [38]. TRIM32 is a
RING finger Ub ligase implicated in innate immunity and has potential to bind E7 from HR α-HPV-16,
-18 and -33, LR HPV-6, and also β-HPV types 8 and 38. TRIM72 has demonstrated the potential to
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bind E7 oncoproteins from certain HR α-HPVs (HPV-16, -18, and -33) and β-HPVs (HPV-8, and -38),
but not a LR HPV-6 E7 oncoprotein [38]. Only TRIM22 has been fully characterized and seems to be
downregulated in HPV-16- and HPV-18-positive cervical cancers [155].
Additional interactions have been identified between the E7 oncoproteins of LR HPV-6, HR
HPV-16, -18, -33, and β-HPV-8 and -38 and RING ubiquitin ligase NEURL1, while only HR (HPV-16,
-18 and -33) and LR (HPV-6) E7 binds to another RING ubiquitin ligase RNF135 [38]. However, the
consequences of these interactions have yet to be investigated. Furthermore, interactions between
E7 oncoproteins and ubiquitin ligase SH3RF1 were detected via GPCA assay, but have not been
additionally confirmed by other interaction assays (34).
5.2. E7 Oncoprotein and Deubiquitinating Enzymes
E7 oncoprotein also interacts with some DUBs; amongst these are USP26 and USP33, which are
ubiquitin carboxyl-terminal hydrolases known to be involved in the ubiquitin-dependent proteolytic
degradation of proteins via the 26S proteasome. Both USP26 and USP33 were identified as interactors
of HR HPVs (HPV-16, -18 and -33), but not of β-HPVs (HPV-8 and -38), and have not so far been
investigated in detail [38]. The USP29, a DUB implicated in thiol-dependent hydrolysis, also interacts
with HR HPV-16, -18 and -33 E7 oncoproteins [38].
USP11, which belongs to a class of DUB that cleaves polyubiquitin chains, and thus inhibits the
proteasome-mediated degradation of target proteins, is on the other hand, the only USP component so
far shown to be bound by E7. USP11 increases the steady state levels of HPV-16 E7 by attenuating
E7 ubiquitination and degradation, thus protecting E7 as well as influencing its effects on cell
proliferation [156]. This interaction results in an increased stability and prolonged half-life of E7, but
also suggests its requirement for modulation of downstream target proteins, subsequently affecting the
biological function of E7, as well as abrogating its contribution to cell transformation.
5.3. E7 Oncoprotein and Proteasome Components
Recent studies have shown that the levels of E7 protein in cancer cells are regulated by
ubiquitin-dependent proteolysis via the 26S proteasome [132,135,157]. Furthermore, E7 seems to
interact with the 26S proteasome subunit 4 (S4) ATPase via E7’s carboxyl-terminal zinc binding motif;
the interaction thus being independent of the E7-pRb interaction. Therefore, E7 might target pRb for
degradation by directly interacting with the 26S proteasome through S4. Moreover, E7 increases the
ATPase activity of S4 and this same pathway was shown to be used by E7 in degrading pRb, with
tumorigenic effect [135,157].
6. Concluding Remarks
The interplay between E6/E7 oncoproteins from various HPV types and the UPS has been shown
to be one of the critical strategies used by these viruses to create an optimal environment in which they
can successfully replicate. However, this process, which is generally highly regulated and controlled
through the various stages of the viral life cycle, can in some instances be perturbed, initially causing
an imbalance in cellular homeostasis, and ultimately resulting in the transformed cell phenotype. As
can be seen from Figures 1 and 2, by interacting with the components of the UPS, viral oncoproteins
modulate numerous cellular functions, which are also necessary for initiation and/or maintenance of
the transformed cellular phenotype. Interestingly, of the large number of α- and β-HPV types that
infect humans, only a small proportion are actually associated with human malignancies. Intriguingly,
as indicated in Tables 1 and 2, it appears that E6/E7 oncoproteins from HR HPVs, which are associated
with various human cancers at different anatomical sites, have been reported to interact with a vast
number of the UPS components, including a number of ubiquitin ligases. In contrast, E6/E7 from
β-HPVs, which are characterized as co-factors in causing skin cancers under specific conditions, interact
with significantly fewer components of the UPS, while E6/E7 from LR types interact with only a few
components of the UPS. All of this suggests that HR HPVs may be more efficiently adapted to evade
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the immune system and maintain persistent infection in the surrounding environment, than LR and
β-HPV types, under permissive and regulated conditions. Consequently, when these conditions are
disordered and the viral oncoproteins become unregulated, this is reflected in their interactions and
modulation of the UPS, and can in turn lead to the formation of a more malignant phenotype, which
is a hallmark of persistent HR HPV infections. Therefore, a better understanding of the interplay
between the UPS and the viral oncoproteins is a pressing need for providing a more comprehensive
network of the cellular pathways affected in the process of carcinogenesis in general, and HPV-induced
carcinogenesis in particular. Furthermore, the development of novel strategies to block the viral
perturbation of these UPS components should be one of the major aims in designing sorely-needed
therapies against HPV-induced malignancies.
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